

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Case Count			1491	62	977
Reaction Count	Blood and lymphatic system disorders	Anaemia	6	1	2
		Hypochromic anaemia	6	0	6
		Normochromic normocytic anaemia	1	0	0
		Aplastic anaemia	2	0	2
		Bone marrow failure	2	0	2
		Pancytopenia	7	0	3
		Thrombocytopenia	10	0	4
		Thrombocytosis	1	0	0
		Splenomegaly	1	0	0
		Eosinophilia	4	0	3
		Leukocytosis	16	1	3
		Lymphocytosis	1	1	0
		Monocytosis	1	0	1
		Neutrophilia	2	0	2
		Eosinopenia	1	0	1
		Leukopenia	30	0	18
		Lymphopenia	3	0	2
		Agranulocytosis	7	0	2
		Febrile neutropenia	4	0	2
		Neutropenia	63	1	34
		Blood and lymphatic system disorders	168	4	87
	Cardiac disorders	Atrioventricular block	2	0	2
		Bundle branch block	1	0	0
		Arrhythmia	4	2	1
		Bradycardia	10	1	7
		Extrasystoles	3	0	2
		Tachycardia	24	0	16
		Atrial fibrillation	7	0	6
		Sinus arrest	1	0	0
		Sinus bradycardia	1	0	0
		Sinus tachycardia	1	0	0
		Supraventricular tachycardia	2	0	0

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Cardiac disorders	Cardiac arrest	9	7	4
		Torsade de pointes	2	0	1
		Ventricular extrasystoles	1	0	1
		Ventricular fibrillation	1	1	1
		Ventricular tachycardia	4	0	3
		Cardiac disorder	2	0	1
		Cyanosis	1	0	1
		Palpitations	4	0	0
		Mitral valve incompetence	1	0	0
		Myocardial infarction	5	0	3
		Cardiac failure	6	0	2
		Cardiac failure acute	1	0	0
		Cardiac failure congestive	1	0	1
		Cardiomyopathy	12	2	3
		Cardiomegaly	3	0	3
		Myocarditis	5	2	0
		Cardiac tamponade	1	0	1
		Pericardial effusion	3	0	1
		Cardiac disorders	118	15	60
	Congenital, familial and genetic disorders	Ebstein's anomaly	1	0	0
		Oesophageal atresia	1	0	1
		Cleft palate	1	0	0
		Cleft lip	1	0	1
		Congenital foot malformation	1	0	0
		Polydactyly	1	0	0
		Congenital brain damage	1	0	1
		Congenital hydrocephalus	1	0	1
		Renal aplasia	1	0	0
		Tracheo-oesophageal fistula	1	0	1
		Congenital, familial and genetic disorders	10	0	5
	Ear and labyrinth disorders	Hyperacusis	1	0	1
		Tinnitus	3	0	1
		Vertigo	2	0	1

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Ear and labyrinth disorders	Ear and labyrinth disorders	6	0	3
	Endocrine disorders	Cushing's syndrome	2	0	1
		Hyperprolactinaemia	13	0	11
		Inappropriate antidiuretic hormone secretion	1	0	1
		Endocrine disorders	16	0	13
	Eye disorders	Cataract	2	0	1
		Eye disorder	1	0	1
		Eye pain	1	0	0
		Periorbital oedema	3	0	2
		Conjunctivitis	4	0	3
		Conjunctival irritation	1	0	0
		Blepharitis	1	0	1
		Blepharospasm	1	0	1
		Eyelid ptosis	2	0	0
		Oculogyric crisis	4	0	3
		Miosis	4	0	3
		Mydriasis	1	0	1
		Photophobia	2	0	1
		Retinal degeneration	1	0	0
		Visual acuity reduced	1	0	1
		Chromatopsia	1	0	1
		Vision blurred	8	0	7
		Visual impairment	7	0	6
		Optic neuropathy	1	0	1
		Eye disorders	46	0	33
	Gastrointestinal disorders	Pancreatitis	7	0	3
		Pancreatitis acute	2	0	1
		Pancreatitis necrotising	1	0	1
		Rectal haemorrhage	1	0	0
		Gastrointestinal haemorrhage	2	0	2
		Haematemesis	1	0	0
		Diarrhoea	8	0	5
		Colonic pseudo-obstruction	1	0	1

Outcome Description

(Causality possible,Causality probable,Causality certain)

Suspect Type

Suspect Code

Case Group

GM

Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Gastrointestinal disorders	Constipation	10	0	7
		Dyspepsia	2	0	0
		Eructation	2	0	1
		Abdominal distension	6	0	4
		Flatulence	7	0	6
		Abdominal pain	6	0	2
		Abdominal pain upper	2	0	2
		Abdominal discomfort	1	0	1
		Dysphagia	6	1	4
		Faecal incontinence	1	0	0
		Nausea	20	0	11
		Vomiting	20	0	14
		Obstruction gastric	1	0	1
		Ileus	1	0	1
		Gastric ulcer	1	0	0
		Oedema mouth	1	0	0
		Mouth ulceration	4	0	3
		Ascites	1	0	1
		Dry mouth	9	0	6
		Salivary hypersecretion	16	0	6
		Salivary gland enlargement	1	0	0
		Swollen tongue	2	0	0
		Tongue discolouration	1	0	1
		Tongue oedema	5	0	3
		Gastrointestinal disorders	149	1	87
	General disorders and administration site conditions	Hyperthermia malignant	1	0	0
		Hypothermia	10	0	8
		Pyrexia	64	3	30
		Death	10	9	6
		Death neonatal	1	0	0
		Sudden death	9	9	3
		Asthenia	4	0	4
		Fatigue	15	0	8

Outcome Description

(Causality possible,Causality probable,Causality certain)

Suspect Type

Suspect Code

Case Group

GM

Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	General disorders and administration site conditions	Malaise	11	1	7
		Sluggishness	1	0	1
		Gait disturbance	15	1	6
		Condition aggravated	7	0	4
		Disease progression	1	0	1
		Disease recurrence	1	0	1
		Foaming at mouth	1	0	0
		Influenza like illness	9	0	5
		Irritability	1	0	1
		Pseudocyst	1	0	1
		Swelling	1	0	0
		Polyserositis	1	0	1
		Face oedema	18	0	16
		Generalised oedema	8	0	6
		Gravitational oedema	17	0	16
		Oedema	17	0	13
		Oedema peripheral	48	0	42
		Chest pain	10	0	6
		Discomfort	1	0	1
		Pain	8	0	8
		Chills	12	0	6
		Feeling abnormal	1	0	1
		Feeling hot	1	0	0
		Feeling jittery	2	0	0
		Feeling of body temperature change	2	0	2
		Hunger	1	0	0
		Thirst	5	0	4
		Drug interaction	6	1	0
		Drug effect decreased	1	0	1
		Drug ineffective	22	4	11
		Paradoxical drug reaction	1	0	1
		Therapeutic response decreased	2	0	1
		Drug withdrawal syndrome	2	0	1

Outcome Description

(Causality possible,Causality probable,Causality certain)

Suspect Type

Suspect Code

Case Group

GM

Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	General disorders and administration site conditions	Drug withdrawal syndrome neonatal	2	0	0
		Fat necrosis	1	0	0
		General disorders and administration site conditions	352	28	223
	Hepatobiliary disorders	Cholecystitis	1	0	0
		Hyperbilirubinaemia	3	0	1
		Jaundice	8	0	6
		Jaundice cholestatic	1	0	0
		Liver injury	3	0	1
		Hepatic function abnormal	59	1	34
		Hepatomegaly	2	0	0
		Hepatosplenomegaly neonatal	1	0	0
		Autoimmune hepatitis	1	0	0
		Hepatic steatosis	3	1	1
		Hepatitis	7	0	1
		Hepatitis fulminant	1	0	0
		Hepatocellular injury	2	0	1
		Hepatobiliary disorders	92	2	45
	Immune system disorders	Hypersensitivity	2	0	0
		Immune system disorders	2	0	0
	Infections and infestations	Cellulitis	1	0	0
		Mastitis	1	0	1
		Eye infection	1	0	1
		Vaginal infection	1	0	1
		Infection	1	0	1
		Bronchitis	1	0	1
		Pneumonia	8	3	4
		Bacteraemia	1	0	1
		Sepsis	2	0	1
		Rash pustular	2	0	1
		Pharyngitis	1	0	0
		Rhinitis	1	0	1
		Urinary tract infection	1	0	0

Outcome Description

(Causality possible,Causality probable,Causality certain)

Suspect Type

Suspect Code

Case Group

GM

Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Infections and infestations	Hepatitis C	1	0	1
		Infections and infestations	23	3	14
	Injury, poisoning and procedural complications	Accidental poisoning	2	2	0
		Poisoning deliberate	1	1	0
		Toxicity to various agents	14	13	3
		Drug exposure during pregnancy	14	0	8
		Subdural haematoma	1	0	0
		Fall	4	0	1
		Incorrect dose administered	3	0	2
		Incorrect route of drug administration	1	0	0
		Accidental drug intake by child	1	0	1
		Accidental overdose	1	0	0
		Intentional overdose	5	0	2
		Overdose	17	3	11
		Post procedural complication	2	0	2
		Injury, poisoning and procedural complications	66	19	30
	Investigations	Cardiac murmur	2	0	2
		Ejection fraction decreased	1	0	0
		Electrocardiogram QT prolonged	12	0	10
		Electrocardiogram T wave inversion	1	0	0
		Electrocardiogram abnormal	5	0	3
		Heart rate decreased	1	0	1
		Heart rate increased	1	0	1
		Heart rate irregular	1	0	1
		Pulse absent	1	1	1
		Sinus rhythm	1	0	1
		Blood pressure increased	1	0	0
		Blood prolactin increased	3	0	1
		Blood testosterone increased	1	0	1
		Blood creatine phosphokinase increased	55	3	28
		Cardiac enzymes increased	1	0	0
		Troponin increased	3	1	0

🔹 Outcome Description

🔹 (Causality possible,Causality probable,Causality certain)

🔹 Suspect Type

🔹 Suspect Code

🔹 Case Group

🔹 GM

🔹 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Investigations	Troponin	1	0	0
		Blood alkaline phosphatase increased	6	0	4
		Blood lactate dehydrogenase increased	2	0	2
		Blood amylase increased	1	0	1
		Lipase increased	1	0	0
		Prothrombin level increased	1	1	0
		Red blood cell sedimentation rate increased	3	0	2
		Platelet count decreased	1	0	0
		Platelet count increased	1	0	1
		Haematocrit decreased	1	0	1
		Haemoglobin decreased	1	0	1
		Lymphocyte count decreased	1	0	0
		Neutrophil count decreased	4	0	3
		White blood cell count decreased	4	0	0
		White blood cell count increased	1	0	0
		Alanine aminotransferase increased	10	0	5
		Ammonia increased	1	0	0
		Aspartate aminotransferase increased	5	0	2
		Blood bilirubin increased	1	0	1
		Gamma-glutamyltransferase increased	8	0	7
		Hepatic enzyme abnormal	1	0	0
		Hepatic enzyme increased	1	0	1
		Liver function test abnormal	15	0	6
		Antinuclear antibody positive	1	0	1
		Immunoglobulins increased	1	0	1
		Blood cholesterol increased	5	0	3
		Blood triglycerides increased	3	0	2
		Blood glucose fluctuation	1	0	1
		Blood glucose increased	6	0	5
		Electroencephalogram abnormal	1	0	1
		Apgar score abnormal	1	0	1
		Body temperature decreased	1	0	0
		Body temperature increased	3	0	0

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Investigations	Weight decreased	4	0	2
		Weight increased	105	1	93
		C-reactive protein increased	3	0	2
		Creatinine renal clearance decreased	2	0	1
		Urine output decreased	1	0	1
		Drug level above therapeutic	2	1	1
		Drug level changed	1	0	0
		Drug level increased	6	1	2
		Blood phosphorus decreased	1	0	0
		Investigations	309	9	204
	Metabolism and nutrition disorders	Ketoacidosis	4	0	3
		Acidosis	1	0	1
		Decreased appetite	3	0	1
		Food craving	1	0	1
		Increased appetite	17	0	16
		Feeding disorder neonatal	1	0	0
		Obesity	4	0	3
		Weight loss poor	1	0	1
		Hypercalcaemia	4	1	3
		Hypocalcaemia	1	1	0
		Diabetic ketoacidosis	4	0	2
		Hyperglycaemic hyperosmolar nonketotic syndrome	1	0	1
		Polydipsia	8	1	6
		Hyperkalaemia	3	0	2
		Hypokalaemia	3	1	1
		Hypernatraemia	1	0	0
		Hyponatraemia	16	2	8
		Dehydration	2	0	1
		Diabetes mellitus	29	0	27
		Gestational diabetes	1	0	1
		Type 1 diabetes mellitus	3	0	3
		Type 2 diabetes mellitus	7	0	7
		Glucose tolerance impaired	3	0	2

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Metabolism and nutrition disorders	Hyperglycaemia	18	0	15
		Hypoglycaemia	1	0	1
		Hypoglycaemia neonatal	1	0	0
		Hypertriglyceridaemia	1	0	1
		Hyperlipidaemia	1	0	0
		Metabolic syndrome	1	0	1
		Hyperammonaemia	1	0	0
		Hyperproteinaemia	1	0	1
		Hypoproteinaemia	3	0	2
		Metabolism and nutrition disorders	146	6	111
	Musculoskeletal and connective tissue disorders	Jaw disorder	1	0	1
		Arthritis	1	0	1
		Arthralgia	10	0	9
		Joint stiffness	1	0	0
		Joint swelling	3	0	3
		Osteoarthritis	4	0	4
		Myalgia	17	0	12
		Muscle spasms	3	0	3
		Muscle twitching	22	0	17
		Hypertonia neonatal	1	0	0
		Muscle rigidity	7	1	3
		Nuchal rigidity	1	0	1
		Muscular weakness	3	0	1
		Rhabdomyolysis	8	0	2
		Mastication disorder	1	0	0
		Mobility decreased	1	0	0
		Musculoskeletal stiffness	11	0	4
		Back pain	1	0	1
		Pain in extremity	3	0	3
		Musculoskeletal and connective tissue disorders	99	1	65
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer female	2	0	2
		Pituitary tumour	1	0	1

Outcome Description

(Causality possible,Causality probable,Causality certain)

Suspect Type

Suspect Code

Case Group

GM

Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Mycosis fungoides	2	2	0
		Neoplasm malignant	1	0	1
		Prolactinoma	1	0	1
		Neoplasms benign, malignant and unspecified (incl cysts and polyps)	7	2	5
	Nervous system disorders	Cerebral haemorrhage	1	1	0
		Cerebral haemorrhage neonatal	1	0	0
		Cerebrovascular accident	4	1	4
		Haemorrhagic stroke	1	1	1
		Cerebrovascular disorder	1	0	1
		Transient ischaemic attack	2	0	1
		Cranial nerve disorder	1	0	1
		VIIth nerve paralysis	1	0	1
		Hypoxic-ischaemic encephalopathy	1	0	1
		Headache	22	1	14
		Dementia	1	0	1
		Dementia with Lewy bodies	1	1	0
		Amnesia	8	0	2
		Memory impairment	2	0	1
		Cognitive disorder	4	0	1
		Disturbance in attention	4	0	2
		Mental impairment	2	1	1
		Choreoathetosis	3	0	2
		Akathisia	27	2	4
		Bradykinesia	3	1	0
		Dyskinesia	18	0	16
		Extrapyramidal disorder	33	1	23
		Hyperkinesia	16	0	11
		Hypokinesia	4	1	4
		Movement disorder	1	0	1
		Tardive dyskinesia	30	1	18
		Dystonia	27	1	19
		Opisthotonus	4	0	2

🔹 Outcome Description

🔹 (Causality possible,Causality probable,Causality certain)

🔹 Suspect Type

🔹 Suspect Code

🔹 Case Group

🔹 GM

🔹 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Nervous system disorders	Hemiparesis	1	0	1
		Paralysis	2	0	2
		Paresis	1	0	0
		Cogwheel rigidity	2	0	0
		Parkinsonian gait	2	0	0
		Parkinsonism	9	2	7
		Asterixis	1	0	0
		Tremor	47	1	26
		Tremor neonatal	1	0	0
		Cerebral cyst	1	0	1
		Hyperreflexia	5	0	1
		Ataxia	13	1	7
		Coordination abnormal	1	0	0
		Nystagmus	1	0	0
		Coma	10	2	6
		Diabetic coma	2	0	2
		Aphasia	2	0	1
		Dysgraphia	1	0	1
		Dyspraxia	1	0	1
		Altered state of consciousness	5	0	2
		Consciousness fluctuating	4	0	2
		Depressed level of consciousness	5	1	2
		Lethargy	2	1	0
		Loss of consciousness	5	0	2
		Sedation	14	2	6
		Somnolence	53	1	34
		Somnolence neonatal	1	0	1
		Syncope	14	0	5
		Motor dysfunction	2	0	2
		Clonus	1	0	0
		Dizziness	22	1	15
		Drooling	3	0	2
		Myoclonus	3	0	1

🔹 Outcome Description

🔹 (Causality possible,Causality probable,Causality certain)

🔹 Suspect Type

🔹 Suspect Code

🔹 Case Group

🔹 GM

🔹 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Nervous system disorders	Unresponsive to stimuli	3	0	1
		Burning sensation	1	0	1
		Formication	1	0	1
		Paraesthesia	5	0	4
		Hypoaesthesia	3	0	3
		Dysarthria	10	0	7
		Incoherent	1	0	0
		Speech disorder	11	0	9
		Visual field defect	1	0	1
		Cholinergic syndrome	1	0	0
		Hypertonia	45	4	19
		Neuroleptic malignant syndrome	72	4	27
		Serotonin syndrome	10	0	1
		Muscle contractions involuntary	1	0	1
		Myasthenia gravis	1	0	0
		Carpal tunnel syndrome	1	0	1
		Neuropathy peripheral	2	0	1
		Petit mal epilepsy	1	0	0
		Convulsion neonatal	2	0	0
		Grand mal convulsion	13	0	8
		Convulsion	54	2	30
		Epilepsy	1	0	0
		Frontal lobe epilepsy	1	0	1
		Hypersomnia	2	0	2
		Brain injury	1	1	0
		Nervous system disorders	704	36	380
	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	3	0	0
		Intra-uterine death	1	0	0
		Foetal distress syndrome	1	0	0
		Foetal growth restriction	1	0	0
		Obstructed labour	1	0	1
		Antepartum haemorrhage	1	0	1
		Premature separation of placenta	1	0	1

🔹 Outcome Description

🔹 (Causality possible,Causality probable,Causality certain)

🔹 Suspect Type

🔹 Suspect Code

🔹 Case Group

🔹 GM

🔹 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Pregnancy, puerperium and perinatal conditions	Pre-eclampsia	1	0	1
		Small for dates baby	1	0	0
		Weight decrease neonatal	1	0	0
		Jaundice neonatal	1	0	1
		Neonatal disorder	1	0	1
		Oligohydramnios	1	0	0
		Pregnancy, puerperium and perinatal conditions	15	0	6
	Psychiatric disorders	Agitation	45	1	22
		Agitation neonatal	2	0	1
		Anxiety	13	0	6
		Nervousness	7	0	2
		Tension	1	0	0
		Fear	2	0	1
		Panic attack	1	0	0
		Neurosis	8	0	4
		Obsessive-compulsive disorder	7	0	4
		Catatonia	10	1	5
		Restlessness	7	0	1
		Bruxism	1	0	1
		Stereotypy	1	0	0
		Dysphemia	2	0	1
		Screaming	1	0	0
		Confusional state	51	4	28
		Disorientation	5	0	2
		Delirium	25	0	13
		Depression	13	0	6
		Depression suicidal	2	0	2
		Depressed mood	3	0	2
		Depersonalisation	3	0	3
		Delusion	5	0	3
		Persecutory delusion	1	0	0
		Hallucination	30	2	15

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Psychiatric disorders	Hallucination, auditory	3	1	0
		Hallucination, visual	2	0	1
		Thinking abnormal	11	1	9
		Ideas of reference	1	0	0
		Impulsive behaviour	1	0	0
		Hypomania	1	0	0
		Mania	16	0	8
		Affect lability	1	0	1
		Flat affect	2	0	2
		Anger	1	0	1
		Dysphoria	1	0	1
		Elevated mood	1	0	0
		Euphoric mood	3	0	2
		Emotional poverty	1	0	1
		Apathy	4	0	2
		Aggression	33	4	10
		Disturbance in social behaviour	1	0	1
		Homicidal ideation	10	1	1
		Paranoia	4	0	1
		Social avoidant behaviour	1	0	1
		Personality disorder	8	0	7
		Abnormal behaviour	6	1	4
		Mental disorder	1	1	0
		Alcohol abuse	1	0	1
		Drug abuse	1	0	0
		Drug dependence	1	0	1
		Intentional drug misuse	1	0	0
		Withdrawal syndrome	16	1	9
		Psychotic disorder	18	1	11
		Schizophreniform disorder	2	0	2
		Schizoaffective disorder	1	0	1
		Schizophrenia	1	0	1
		Orgasmic sensation decreased	1	0	1

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Psychiatric disorders	Libido decreased	1	0	1
		Loss of libido	1	0	1
		Insomnia	17	0	11
		Abnormal sleep-related event	1	0	0
		Nightmare	4	0	2
		Somnambulism	2	0	2
		Sleep disorder	2	0	2
		Completed suicide	7	7	2
		Intentional self-injury	5	0	2
		Self injurious behaviour	2	0	1
		Suicidal behaviour	2	0	0
		Suicidal ideation	34	1	7
		Suicide attempt	36	3	7
		Psychiatric disorders	516	30	240
	Renal and urinary disorders	Nephrotic syndrome	2	0	1
		Tubulointerstitial nephritis	2	0	2
		Anuria	1	0	0
		Renal failure	1	0	1
		Renal failure acute	7	1	3
		Renal impairment	5	0	2
		Enuresis	1	0	0
		Incontinence	2	1	2
		Pollakiuria	1	0	1
		Urinary hesitation	1	0	0
		Urinary incontinence	14	0	9
		Urinary retention	11	0	8
		Albuminuria	3	0	2
		Crystalluria	1	0	0
		Haematuria	2	0	2
		Nocturia	1	0	1
		Polyuria	9	0	7
		Renal and urinary disorders	64	2	41
Reaction Count	Reproductive system and breast disorders	Breast enlargement	3	0	2

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Reproductive system and breast disorders	Breast mass	2	0	1
		Gynaecomastia	14	0	11
		Breast pain	3	0	2
		Nipple pain	1	0	1
		Galactorrhoea	11	0	11
		Lactation disorder	1	0	1
		Menstrual disorder	1	0	1
		Amenorrhoea	11	0	10
		Ovarian cyst	1	0	1
		Polycystic ovaries	1	0	1
		Prostatic disorder	1	0	1
		Genital ulceration	1	0	0
		Ejaculation failure	1	0	1
		Erectile dysfunction	4	0	4
		Priapism	10	0	9
		Testicular disorder	1	0	1
		Vaginal haemorrhage	2	0	0
		Reproductive system and breast disorders	69	0	58
	Respiratory, thoracic and mediastinal disorders	Asthma	2	1	1
		Bronchospasm	5	0	4
		Bronchial obstruction	1	0	1
		Pneumonia aspiration	2	1	2
		Pulmonary fibrosis	2	1	1
		Pulmonary oedema	1	0	1
		Infantile apnoeic attack	1	0	0
		Pleural effusion	1	0	1
		Pulmonary hypertension	1	0	0
		Pulmonary embolism	4	1	1
		Apnoea	2	0	2
		Dyspnoea	18	2	10
		Hyperventilation	2	0	0
		Respiratory arrest	3	0	0
		Respiratory depression	6	3	2

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	1	0	0
		Tachypnoea	2	0	0
		Asphyxia	1	1	0
		Hypoxia	2	1	0
		Cough	4	0	3
		Sputum increased	2	0	2
		Respiratory failure	2	0	2
		Aspiration	1	1	0
		Respiratory disorder	1	0	1
		Oropharyngeal pain	1	0	0
		Epistaxis	4	0	3
		Nasal polyps	1	0	1
		Respiratory, thoracic and mediastinal disorders	73	12	38
	Skin and subcutaneous tissue disorders	Angioedema	4	0	2
		Urticaria	14	0	10
		Lichenoid keratosis	1	0	1
		Skin striae	1	0	1
		Leukoplakia	1	0	0
		Blister	2	0	2
		Dermatitis bullous	3	0	3
		Pemphigoid	1	0	1
		Stevens-Johnson syndrome	3	0	3
		Skin discolouration	1	0	1
		Skin odour abnormal	1	0	1
		Skin reaction	1	0	0
		Eczema	1	0	1
		Drug eruption	1	0	1
		Erythema	3	0	2
		Rash erythematous	6	0	6
		Skin exfoliation	2	0	1
		Necrobiosis lipoidica diabetorum	1	0	0
		Photosensitivity reaction	9	0	9

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Skin and subcutaneous tissue disorders	Pruritus	15	0	9
		Rash pruritic	1	0	0
		Psoriasis	2	0	1
		Rash	41	0	24
		Rash generalised	2	1	2
		Rash macular	3	0	1
		Rash maculo-papular	10	0	8
		Rash vesicular	1	0	1
		Acne	9	0	7
		Alopecia	7	0	7
		Hyperhidrosis	27	1	17
		Nail disorder	1	0	1
		Petechiae	1	0	0
		Purpura	7	0	4
		Skin and subcutaneous tissue disorders	183	2	127
	Social circumstances	Physical assault	2	0	2
		Activities of daily living impaired	1	0	1
		Treatment noncompliance	1	0	0
		Social circumstances	4	0	3
	Surgical and medical procedures	Gastrectomy	1	0	1
		Hospitalisation	1	1	1
		Off label use	4	0	4
		Therapy regimen changed	9	0	6
		Surgical and medical procedures	15	1	12
	Vascular disorders	Peripheral ischaemia	1	0	0
		Blood pressure fluctuation	2	0	0
		Circulatory collapse	6	1	3
		Hypotension	21	0	14
		Orthostatic hypotension	14	0	10
		Arterial thrombosis limb	1	0	1
		Deep vein thrombosis	5	0	2
		Vasodilatation	3	0	2
		Flushing	2	0	2

 Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Olanzapine

Medicine summary - Antipsychotics- olanzapine

			Case Group	Death Outcomes	Sole
Reaction Count	Vascular disorders	Hot flush	1	0	1
		Pallor	3	1	1
		Hypertension	17	1	13
		Vascular disorders	76	3	49
	Reaction		3328	176	1939

⊘ Rows are suppressed based on zeros and empty cells for Case Group

🔹 Outcome Description

🔹 (Causality possible,Causality probable,Causality certain)

🔹 Suspect Type

🔹 Suspect Code

🔹 Case Group

🔹 GM

🔹 Olanzapine